The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain
Official Title: A Multicentre Randomised Trial Of Single Dose Radiotherapy Compared To Ibandronate For Localised Metastatic Bone Pain
Study ID: NCT00082927
Brief Summary: RATIONALE: Ibandronate may be effective in reducing bone pain caused by metastatic cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether ibandronate is more effective than standard treatment with radiation therapy in treating metastatic bone pain. PURPOSE: This phase III randomized clinical trial is studying ibandronate to see how well it works compared to single-dose local radiation therapy in treating patients with localized metastatic bone pain.
Detailed Description: OBJECTIVES: Primary * Compare pain response at 4 and 12 weeks post-treatment in patients with localized metastatic bone pain treated with single-dose ibandronate vs single-dose local radiotherapy . Secondary * Compare the quality of life of patients treated with these regimens. * Correlate urinary markers of osteoclast activity (pyridinoline and deoxypyridinoline) with the clinical outcome of patients treated with these regimens. OUTLINE: This is a randomized, open-label, crossover, multicenter study. Patients are stratified according to primary tumor type and participating center. Patients are randomized into 1 of 2 treatment arms. * Arm I: Patients receive a single dose of local radiotherapy to the site of pain (8Gy/1f). * Arm II: Patients receive a single dose of ibandronate IV over 15 minutes. Patients who do not achieve a partial or complete response at 4 weeks crossover to the alternate arm. Quality of life is assessed at baseline and then at 4 and 12 weeks. Pain is assessed at baseline, at 4, 8, and 12 weeks, and then at 6 months. Patients are followed at 4, 8, and 12 weeks and then at 6 and 12 months. Peer Reviewed and Funded or Endorsed by Cancer Research UK PROJECTED ACCRUAL: A total of 470 patients (235 per treatment arm) will be accrued for this study.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
William Harvey Hospital, Ashford-Kent, England, United Kingdom
North Devon District Hospital, Barnstaple, England, United Kingdom
Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom
Royal United Hospital, Bath, England, United Kingdom
Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom
Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom
Queen's Hospital, Burton-upon-Trent, England, United Kingdom
Kent and Canterbury Hospital, Canterbury, England, United Kingdom
Cumberland Infirmary, Carlisle, England, United Kingdom
Essex County Hospital, Colchester, England, United Kingdom
Walsgrave Hospital, Coventry, England, United Kingdom
Mayday University Hospital, Croydon, England, United Kingdom
Russells Hall Hospital, Dudley, England, United Kingdom
Eastbourne District General Hospital, Eastbourne, England, United Kingdom
Royal Devon and Exeter Hospital, Exeter, England, United Kingdom
Diana Princess of Wales Hospital, Grimsby, England, United Kingdom
St. Luke's Cancer Centre at Royal Surrey County Hospital, Guildford, England, United Kingdom
Harrogate District Hospital, Harrogate, England, United Kingdom
Kidderminster Hospital, Kidderminster Worcestershire, England, United Kingdom
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
Lincoln County Hospital, Lincoln, England, United Kingdom
Cancer Research UK and University College London Cancer Trials Centre, London, England, United Kingdom
Royal Marsden - London, London, England, United Kingdom
St. Mary's Hospital, London, England, United Kingdom
Charing Cross Hospital, London, England, United Kingdom
Clatterbridge Centre for Oncology, Merseyside, England, United Kingdom
Northampton General Hospital NHS Trust, Northampton, England, United Kingdom
Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom
King's Mills Hospital, Nottinghamshire, England, United Kingdom
Nottingham City Hospital NHS Trust, Nottingham, England, United Kingdom
George Eliot Hospital, Nuneaton, England, United Kingdom
Alexandra Healthcare NHS, Redditch, Worcestershire, England, United Kingdom
Oldchurch Hospital, Romford, England, United Kingdom
Conquest Hospital, Saint Leonards-on-Sea, England, United Kingdom
Scarborough General Hospital, Scarborough, England, United Kingdom
Scunthorpe General Hospital, Scunthorpe, England, United Kingdom
Royal Shrewsbury Hospital, Shrewsbury, England, United Kingdom
Southampton General Hospital, Southampton, England, United Kingdom
Royal Marsden - Surrey, Sutton, England, United Kingdom
Musgrove Park Hospital, Taunton, England, United Kingdom
Torbay Hospital, Torquay, England, United Kingdom
Warrington Hospital NHS Trust, Warrington, England, United Kingdom
Warwick Hospital, Warwick, England, United Kingdom
Sandwell General Hospital, West Bromwich, England, United Kingdom
Weston General Hospital, Weston-super-Mare, England, United Kingdom
West Cumberland Hospital, Whitehaven, England, United Kingdom
New Cross Hospital, Wolverhampton, England, United Kingdom
Worthing Hospital, Worthing, England, United Kingdom
Yeovil District Hospital, Yeovil, England, United Kingdom
Cancer Care Centre at York Hospital, York, England, United Kingdom
Ninewells Hospital, Dundee, Scotland, United Kingdom
Glan Clwyd Hospital, Rhyl, Denbighshire, Wales, United Kingdom
Name: Heather Purnell
Affiliation: Cancer Research UK
Role:
Name: Katherine Monson
Affiliation: Cancer Research UK
Role: